ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,588.13
      -0.81%
      US Tech 100
      19,717.20
      -1.99%
      Dow Jones
      39,767.20
      0.12%
      Brent Oil
      84.94
      -0.13%
      Bitcoin
      57,568.74
      -0.33%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. HUTCHMED China Limited (HCM)

      7. HUTCHMED China Limited (HCM) News

      HCM

      HUTCHMED China (HCM)

      HUTCHMED China Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:HCM
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      03/01/20226:40AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      03/01/20223:30AMGlobeNewswire Inc.HUTCHMED Receives Approval to Commercialize ELUNATE® in MacauNASDAQ:HCMHUTCHMED China Limited
      02/11/202211:21AMEdgar (US Regulatory)Schedule 13gNASDAQ:HCMHUTCHMED China Limited
      02/10/20223:06AMGlobeNewswire Inc.Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLCNASDAQ:HCMHUTCHMED China Limited
      02/07/20226:12AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      02/07/20223:30AMGlobeNewswire Inc.HUTCHMED to Announce 2021 Final ResultsNASDAQ:HCMHUTCHMED China Limited
      02/04/20224:30AMGlobeNewswire Inc.HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in ChinaNASDAQ:HCMHUTCHMED China Limited
      01/20/20226:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      01/19/20227:00PMGlobeNewswire Inc.HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in ChinaNASDAQ:HCMHUTCHMED China Limited
      01/19/20226:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      01/18/20227:00PMGlobeNewswire Inc.HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers SymposiumNASDAQ:HCMHUTCHMED China Limited
      01/18/20226:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      01/12/20226:13AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      01/12/20226:00AMGlobeNewswire Inc.HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune ThrombocytopeniaNASDAQ:HCMHUTCHMED China Limited
      01/09/20227:00PMGlobeNewswire Inc.HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in ChinaNASDAQ:HCMHUTCHMED China Limited
      01/03/20226:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      12/20/20216:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      12/19/20217:00PMGlobeNewswire Inc.HUTCHMED Included in FTSE Russell IndexesNASDAQ:HCMHUTCHMED China Limited
      12/14/202112:00AMGlobeNewswire Inc.HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual MeetingNASDAQ:HCMHUTCHMED China Limited
      12/10/20216:11AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      12/10/20215:00AMGlobeNewswire Inc.HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 MeetingNASDAQ:HCMHUTCHMED China Limited
      12/06/20216:12AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      12/05/20217:00PMGlobeNewswire Inc.HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
      12/03/202112:00AMGlobeNewswire Inc.HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in ChinaNASDAQ:HCMHUTCHMED China Limited
      11/24/20216:40AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:HCMHUTCHMED China Limited
      11/23/20217:00PMGlobeNewswire Inc.HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor TherapyNASDAQ:HCMHUTCHMED China Limited
      11/19/202110:59AMPR Newswire (Canada)Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewingNASDAQ:HCMHUTCHMED China Limited
      11/19/20219:54AMPR Newswire (US)Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewingNASDAQ:HCMHUTCHMED China Limited
      11/11/20218:35AMPR Newswire (Canada)International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021NASDAQ:HCMHUTCHMED China Limited
       Showing the most relevant articles for your search:NASDAQ:HCM